These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Neuroleptic rechallenge with aripiprazole in a patient with previously documented neuroleptic malignant syndrome. Trutia A, Bledowski J, Pandurangi A, Kahn DA. J Psychiatr Pract; 2008 Nov; 14(6):398-402. PubMed ID: 19057242 [No Abstract] [Full Text] [Related]
7. [A case of malignant neuroleptic syndrome with rhabdomyolysis and a therapeutic trial using physostigmine]. Krull F, Risse A. Fortschr Neurol Psychiatr; 1986 Dec; 54(12):398-401. PubMed ID: 2880787 [Abstract] [Full Text] [Related]
9. Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases. Nisijima K, Ishiguro T. J ECT; 1999 Jun; 15(2):158-63. PubMed ID: 10378156 [Abstract] [Full Text] [Related]
10. [Hyperthermia with acute rhabdomyolysis in a psychotic treated with neuroleptics]. Reis J, Felten P, Rumbach L, Collard M. Rev Neurol (Paris); 1983 Jun; 139(10):595-6. PubMed ID: 6139869 [Abstract] [Full Text] [Related]
11. The myth of elevated serum creatine phosphokinase level and neuroleptic malignant syndrome. Adityanjee. Br J Psychiatry; 1991 May; 158():706-7. PubMed ID: 1677602 [No Abstract] [Full Text] [Related]
12. Neuroleptic malignant syndrome: a preventive program. Fernando ML, Manchanda R, Kirk C. J Psychiatry Neurosci; 1992 Mar; 17(1):31-3. PubMed ID: 1349827 [Abstract] [Full Text] [Related]
13. [Differential diagnosis of acute life threatening catatonia and malignant neuroleptic syndrome--a case report]. Hermle L, Oepen G. Fortschr Neurol Psychiatr; 1986 Jun; 54(6):189-95. PubMed ID: 2873091 [Abstract] [Full Text] [Related]
14. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. Ozen ME, Yumru M, Savas HA, Cansel N, Herken H. World J Biol Psychiatry; 2007 Jun; 8(1):42-4. PubMed ID: 17366349 [Abstract] [Full Text] [Related]
15. Risperidone-induced marked elevation of serum creatine kinase in adolescence. A case report. Holtmann M, Meyer AE, Pitzer M, Schmidt MH. Pharmacopsychiatry; 2003 Nov; 36(6):317-8. PubMed ID: 14663658 [Abstract] [Full Text] [Related]
16. Neuroleptic rechallenge after neuroleptic malignant syndrome. Giacardi-Paty M, Bottai T, Pujalte D, Lainey E, Petit P. Br J Psychiatry; 1993 Jul; 163():121-2. PubMed ID: 8102585 [No Abstract] [Full Text] [Related]
17. [Neuroleptic malignant syndrome]. Dahm JB, Trenckmann U. Med Klin (Munich); 1991 Nov 15; 86(11):601-4. PubMed ID: 1685215 [No Abstract] [Full Text] [Related]
18. [Diagnostic and therapeutic aspects of neuroleptic malignant syndrome based on 12 cases]. Sczesni B, Becker H, Schröder J, Bittkau S, von Baumgarten F, Truong DD, Przuntek H. Wien Klin Wochenschr; 1991 Nov 15; 103(1):21-6. PubMed ID: 1673042 [No Abstract] [Full Text] [Related]
19. Endovascular cooling in a patient with neuroleptic malignant syndrome. Diedler J, Mellado P, Veltkamp R. J Neurol Sci; 2008 Jan 15; 264(1-2):163-5. PubMed ID: 17706678 [Abstract] [Full Text] [Related]
20. Does electroconvulsive therapy exacerbate the elevation of creatinine phosphokinase caused by neuroleptics. Geizer M, Ancill R. Can J Psychiatry; 1996 Mar 15; 41(2):131. PubMed ID: 8705961 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]